Tirofiban With Blood-Thinning Pills for Mild Stroke
Tests tirofiban with blood-thinning pills in adults with mild acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
Key facts
- Where
- Bayan Nur, Huai'an, Shijiazhuang, Suqian, Suzhou, Taizhou, Tianjin, Xi'an, Xianyang, and Zhoukou, ChinaSee the 18 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07095790, who can take part
Where in China
- WuYuan County People's HospitalBayan Nur, ChinaTaking people
- Huai'an First People's HospitalHuai'an, ChinaTaking people
- Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaTaking people
- Jiangsu Province （Suqian）HospitalSuqian, ChinaTaking people
- Affiliated Jiangsu Shengze Hospital of Nanjing Medical UniversitySuzhou, ChinaTaking people
- Changshu No.1 People's HospitalSuzhou, ChinaTaking people
- First People's Hospital of KunshanSuzhou, ChinaTaking people
- Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
- Suzhou Municipal Hospital of Anhui ProvinceSuzhou, ChinaTaking people
- Suzhou Ninth People's HospitalSuzhou, ChinaTaking people
- Suzhou Xiangcheng People's HospitalSuzhou, ChinaTaking people
- Taicang TCM Hospital Affiliated to Nanjing University of Chinese MedicineSuzhou, ChinaTaking people
- Zhangjiagang Hospital of Traditional Chinese MedicineSuzhou, ChinaTaking people
- Taixing Second People's HospitalTaizhou, ChinaTaking people
- Second Hospital of Tianjin Medical UniversityTianjin, ChinaTaking people
- Nuclear Industry 417 HospitalXi'an, ChinaTaking people
- First People's Hospital of XianyangXianyang, ChinaTaking people
- Taikang Xian People's HospitalZhoukou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Soochow University
- Trial code
- NCT07095790
- Record updated
- 31 July 2025
- Original description
This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.Read full original descriptionShow less
Tirofiban With Sequential Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone in Mild Acute Ischemic Stroke (TiMIS): A Multicenter, Open-Label, Blinded-Endpoint, Parallel-Controlled, Randomized Clinical Trial
This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.
Inclusion: Age: 18-80 years old; Acute mild non-cardioembolic stroke; NIHSS score ≤5; Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours; The investigational drug can be administered within 48 hours of symptom onset; Signed informed consent by the patient or legally authorized representative.
Exclusion: Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment); Major surgery within 14 days; Intracranial hemorrhage confirmed by imaging; Pre-stroke modified Rankin Scale (mRS) score ≥2; History of primary intracerebral hemorrhage; History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage); Major systemic bleeding within 30 days; Known allergy or contraindication to tirofiban or aspirin; Any terminal illness with life expectancy <6 months; Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%; Active bleeding, including laboratory evidence of coagulopathy (platelet count <100 × 10⁹/L, activated partial thromboplastin time >50 seconds, or international normalized ratio >1.7), or treatment with direct oral anticoagulants within the preceding 48 hours; Baseline platelet count <100 × 10⁹/L; Severe renal dysfunction (glomerular filtration rate <30 mL/min or serum creatinine >220 μmol/L [2.5 mg/dL]); Untreated or inadequately treated intracranial aneurysm or vascular malformation; Persistently elevated blood pressure (systolic >180 mmHg or diastolic >110 mmHg) despite treatment; Current pregnancy or lactation; Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter).